 |
|
|
| |
Comprehensive Assessment of Resistance Mutations Selected by Dolutegravir (DTG) in Subjects Failing DTG-Monotherapy after Switching from other Therapies (Redomo Study)
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
CROI: DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD
CROI: Dolutegravir as Maintenance Monotherapy for HIV-1: a Randomized Clinical Trial - (02/23/17)
CROI: Promising Results of Lamivudine + Dolutegravir Maintenance Therapy in ANRS 167 Lamidol Trial - (02/23/17)
Blanco JL1, Oldenbuettel C2, Thomas R3, Mallolas J1, Wolf E2,
Brenner BG4,Spinner CD2, Wainberg MA4, Martinez E1
1 Hospital Clinic, Barcelona, Spain. 2 MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany. 3 Clinique Actuel, Montreal, Quebec, Canada. 4 McGill AIDS Centre Montreal, Quebec, Canada
|
| |
|
|
|
|
|
